These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

869 related articles for article (PubMed ID: 31445768)

  • 41. Stage migration in breast cancer: surgical decisions concerning isolated tumour cells and micro-metastases in the sentinel lymph node.
    de Widt-Levert L; Tjan-Heijnen V; Bult P; Ruers T; Wobbes T
    Eur J Surg Oncol; 2003 Apr; 29(3):216-20. PubMed ID: 12657229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Surgical management of early stage invasive breast cancer: a practice guideline.
    McCready D; Holloway C; Shelley W; Down N; Robinson P; Sinclair S; Mirsky D; ;
    Can J Surg; 2005 Jun; 48(3):185-94. PubMed ID: 16013621
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
    Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
    Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Axillary lymph node treatment in breast cancer: an update.
    Williams PA; Suggs J; Mangana SH
    J Miss State Med Assoc; 2014 May; 55(5):145-7. PubMed ID: 25112128
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.
    Veronesi U; Paganelli G; Galimberti V; Viale G; Zurrida S; Bedoni M; Costa A; de Cicco C; Geraghty JG; Luini A; Sacchini V; Veronesi P
    Lancet; 1997 Jun; 349(9069):1864-7. PubMed ID: 9217757
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing second echelon lymph nodes during sentinel lymph node biopsy: can we have more accurate axillary treatment for breast cancer patients?
    Chen K; Jia W; Rao N; Deng H; Jin L; Song E; Su F
    Med Hypotheses; 2011 Dec; 77(6):987-9. PubMed ID: 21908107
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Axillary recurrence in women with a negative sentinel lymph node and no axillary dissection in breast cancer.
    Palesty JA; Foster JM; Hurd TC; Watroba N; Rezaishiraz H; Edge SB
    J Surg Oncol; 2006 Feb; 93(2):129-32. PubMed ID: 16425295
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unnecessary axillary surgery for patients with node-negative breast cancer undergoing total mastectomy.
    Olaya W; Morgan JW; Lum SS
    Arch Surg; 2011 Sep; 146(9):1029-33. PubMed ID: 21930999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prediction of additional lymph node involvement in breast cancer patients with positive sentinel lymph nodes.
    Pohlodek K; Bozikova S; Meciarova I; Mucha V; Bartova M; Ondrias F
    Neoplasma; 2016; 63(3):427-34. PubMed ID: 26925789
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diminishing morbidity with the increased use of sentinel node biopsy in breast carcinoma.
    Bafford A; Gadd M; Gu X; Lipsitz S; Golshan M
    Am J Surg; 2010 Sep; 200(3):374-7. PubMed ID: 20409517
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Sentinel lymph node status and axillary lymph node dissection in the surgical treatment of breast cancer].
    Cserni G
    Orv Hetil; 2014 Feb; 155(6):203-15. PubMed ID: 24486844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.
    Mansel RE; Fallowfield L; Kissin M; Goyal A; Newcombe RG; Dixon JM; Yiangou C; Horgan K; Bundred N; Monypenny I; England D; Sibbering M; Abdullah TI; Barr L; Chetty U; Sinnett DH; Fleissig A; Clarke D; Ell PJ
    J Natl Cancer Inst; 2006 May; 98(9):599-609. PubMed ID: 16670385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
    Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
    Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
    Tvedskov TF
    Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disparities of Management of the Axilla in Women With Clinically Node Negative Breast Cancer.
    Aubry S; Strassle PD; Maduekwe U; Downs-Canner S
    J Surg Res; 2020 Dec; 256():13-22. PubMed ID: 32679224
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
    van Roozendaal LM; de Wilt JH; van Dalen T; van der Hage JA; Strobbe LJ; Boersma LJ; Linn SC; Lobbes MB; Poortmans PM; Tjan-Heijnen VC; Van de Vijver KK; de Vries J; Westenberg AH; Kessels AG; Smidt ML
    BMC Cancer; 2015 Sep; 15():610. PubMed ID: 26335105
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice.
    Garcia-Etienne CA; Mansel RE; Tomatis M; Heil J; Biganzoli L; Ferrari A; Marotti L; Sgarella A; Ponti A;
    Breast; 2019 Jun; 45():89-96. PubMed ID: 30925382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.